Linked Life Data

16397514

Source:http://linkedlifedata.com/resource/pubmed/id/16397514

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-3-17
pubmed:abstractText
This study analysed the efficacy of an angiotensin receptor blocker-based treatment algorithm for achieving goal blood pressure (BP) in patients with stage 1 (systolic BP (SBP) 140-159 mmHg or diastolic BP (DBP) 90-99 mmHg) or stage 2 (SBP > or = 160 mmHg or DBP > or = 100 mmHg) hypertension. In this 24-week, open-label, multicentre study, patients followed a six-step algorithm until goal BP (< or = 130/85 mmHg) was attained. Initially, olmesartan medoxomil 20 mg/day was administered for 4 weeks. The regimen was modified every 4 weeks until goal BP was attained: increase olmesartan medoxomil to 40 mg/day; add hydrochlorothiazide (HCTZ) 12.5 mg/day; increase HCTZ to 25 mg/day; add amlodipine besylate 5 mg/day; increase amlodipine besylate to 10 mg/day. In patients with stage 1 hypertension, 80% (63/79) and 56% (44/79) achieved BP goals of < or = 140/90 mmHg and < or = 130/85 mmHg, respectively, with olmesartan medoxomil monotherapy (94% (74/79) and 89% (70/79) with olmesartan medoxomil/HCTZ double therapy, and 96% (76/79) and 98% (77/79) with addition of amlodipine besylate (triple therapy)). Mean SBP/DBP reductions were 16.7/11.6, 24.8/15.8, and 26.4/16.5 mmHg for mono-, double-, and triple-therapy, respectively. In patients with stage 2 hypertension, 42% (42/100) and 19% (19/100) achieved BP goals of < or = 140/90 mmHg and < or = 130/85 mmHg, respectively, with monotherapy (75% (75/100) and 54% (54/100) with double therapy, and 90% (90/100) and 81% (81/100) with triple-therapy). Mean SBP/DBP reductions in stage 2 patients were 18.4/10.0, 32.7/16.3, and 39.1/19.4 mmHg for mono-, double, and triple therapy, respectively. Overall, most patients with stage 1 or stage 2 hypertension achieved goal BP.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0950-9240
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
255-62
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16397514-Adult, pubmed-meshheading:16397514-Aged, pubmed-meshheading:16397514-Aged, 80 and over, pubmed-meshheading:16397514-Algorithms, pubmed-meshheading:16397514-Amlodipine, pubmed-meshheading:16397514-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:16397514-Blood Pressure, pubmed-meshheading:16397514-Calcium Channel Blockers, pubmed-meshheading:16397514-Diuretics, pubmed-meshheading:16397514-Drug Therapy, Combination, pubmed-meshheading:16397514-Female, pubmed-meshheading:16397514-Follow-Up Studies, pubmed-meshheading:16397514-Humans, pubmed-meshheading:16397514-Hydrochlorothiazide, pubmed-meshheading:16397514-Hypertension, pubmed-meshheading:16397514-Imidazoles, pubmed-meshheading:16397514-Male, pubmed-meshheading:16397514-Middle Aged, pubmed-meshheading:16397514-Severity of Illness Index, pubmed-meshheading:16397514-Tetrazoles, pubmed-meshheading:16397514-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.
pubmed:affiliation
Orange County Research Center, Tustin, CA 92780, USA. JMNeutel@aol.com
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study